Almotriptan
- Generic Name
- Almotriptan
- Brand Names
- Axert
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2S
- CAS Number
- 154323-57-6
- Unique Ingredient Identifier
- 1O4XL5SN61
- Background
Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Almotriptan does not prevent migraine attacks.
- Indication
For the treatment of acute migraine headache in adults
- Associated Conditions
- Migraine
Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
- Conditions
- Migraine With AuraMigraine Without Aura
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Messoud Ashina, MD
- Target Recruit Count
- 645
- Registration Number
- NCT05214001
- Locations
- 🇩🇰
Danish Headache Center, Glostrup, Denmark
Detoxification and Treatment of Subjects With Medication Overuse Headache
- Conditions
- Analgesic Rebound Headache
- First Posted Date
- 2007-02-08
- Last Posted Date
- 2007-02-08
- Lead Sponsor
- The New England Center for Headache, P.C.
- Target Recruit Count
- 60
- Registration Number
- NCT00432549
- Locations
- 🇺🇸
The New England Center for Headache, P.C., Stamford, Connecticut, United States
A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2014-02-21
- Lead Sponsor
- Janssen-Ortho LLC
- Target Recruit Count
- 447
- Registration Number
- NCT00257010
Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers
- Conditions
- SinusitisMigraine
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-05-06
- Lead Sponsor
- Clinvest
- Target Recruit Count
- 50
- Registration Number
- NCT00208065
- Locations
- 🇺🇸
Clinvest, Inc., Springfield, Missouri, United States
Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
- Conditions
- MigraineClassic MigraineCommon Migraine
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen-Ortho LLC
- Target Recruit Count
- 406
- Registration Number
- NCT00210496
A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache
- Conditions
- Migraine
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen-Ortho LLC
- Target Recruit Count
- 378
- Registration Number
- NCT00210509
A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
- Conditions
- Migraine
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen-Ortho LLC
- Target Recruit Count
- 866
- Registration Number
- NCT00210483
The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain
- Conditions
- Migraine
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho-McNeil Neurologics, Inc.
- Target Recruit Count
- 1450
- Registration Number
- NCT00212823
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.